2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4475 Time of infusion does not impact outcomes following CAR T cell therapy in B cell lymphoma: A pooled analysis of 1,545 clinical trial patients

Soon Jye Kho, PhD, Arsalan Anwar, MS2, Sheila Diamond, MS, CGC3, Penelope Lafeuille, MS4, David Aaron Russler-Germain, MD, PhD5, Mark Raymond Dowling, PhD6, Michael Dickinson, MBBS (Hons), DMedSci FRACP, FRCPA7, Edward R. Scheffer Cliff, MD, MPH8
1 Medidata Solutions, a Dassault Systèmes company, New York, New York, United States
2 Medidata Solutions, a Dassault Systèmes company, New York, New York, United States
3 Medidata Solutions, a Dassault Systèmes company, New York, New York, United States
4 Medidata Solutions, a Dassault Systèmes company, New York, New York, United States
5 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University, St. Louis, Missouri, United States
6 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
7 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
8 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia

Background:
Chimeric antigen receptor (CAR) T-cell therapy is a major advance in the treatment of relapsed/refractory B-cell lymphomas (BCL). Circadian rhythms may influence immune effector cell function; retrospective studies suggest that time of administration may influence immune checkpoint inhibitor efficacy in solid tumors. Observational studies of CAR T time of infusion in BCL yielded conflicting results: one international study of 1,052 patients (Luan et al, Blood, 2026) reported that morning infusions were associated with higher complete response rates (CRR) and superior progression free survival (PFS), compared to afternoon infusions. Conversely, an Australian study of 584 patients (Dowling et al, Blood, 2026) found no association between time of infusion and clinical outcomes, creating unresolved equipoise. To further investigate this question, we evaluated the impact of infusion time on therapeutic outcomes in a large cohort of BCL patients, pooled from clinical trials, which may be less impacted by residual confounding than observational data.

Methods: 
We pooled anonymized patient-level data through Medidata Clinical Cloud® across 9 clinical trials. Patients were stratified into two groups based on time of CAR T cell infusion: before versus at or after 12pm. Baseline demographics and clinical characteristics were analyzed using descriptive statistics. CRR and objective response rates (ORR) were compared using the Chi-square test. The Kaplan-Meier (KM) method was used to estimate PFS and overall survival (OS), with differences compared via log rank test. Infusion time was also modeled as a continuous variable using Cox proportional hazards regression: (1) univariate and (2) multivariate, adjusted for age, ECOG status > 1, bulky disease, number of prior lines of therapy, CAR T type (41BB vs CD28 costimulatory domain) and aggressive BCL vs other BCL. Key sensitivity analyses were also performed.

Results:
1,545 patients with BCL received CAR T in clinical trials, of whom 1001 had large BCL, 185 had mantle cell lymphoma (MCL), 266 had follicular lymphoma (FL) and 90 had marginal zone lymphoma (MZL). Median infusion time was 12:30pm (interquartile range: 11:28am-1:56pm); 554 patients received morning (AM) CAR T infusion while 988 received CAR T in the afternoon (PM). Baseline characteristics were described (AM vs PM infusion): median age (61 vs 61 years, p=0.967), male sex (63% vs 66%, p=0.371), white race (76% vs 80%, p=0.324), hispanic ethnicity (8% vs 7%, p=0.336), ECOG score ≤1 (97% vs 97%, p=0.705), bulky disease (23% vs 24%, p=0.068), received bridging therapy (41% vs 35%, p=0.027), pre-lymphodepletion (LD) LDH (222 vs 252 U/L,p= 0.002), pre-LD CRP (18.0 vs 19.6 mg/L, p=0.59), pre-LD albumin: (36 vs 35 g/L, p=0.69), pre-LD platelet (125 vs 126 10^9/L, p=0.9).

Response rates, PFS and OS were similar between groups. CRR was 65% in the AM group vs 66% in the PM group (p=0.967). ORR was 83% in the AM vs 82% in the PM group (p=0.59). Median PFS was 26 months for the AM group vs 24 months for the PM group (Log-rank p=0.59). OS was also similar (log-rank p=0.79; median OS 61 vs 49 months). The apparent difference in median OS is explained by reduced numbers at risk at that time point, with KM curves that skim the median (e.g. Fojo & Bates, JAMA Oncol, 2025). 

When analyzed as a continuous variable, time of infusion was not associated with either PFS (Univariate HR: 1.00, 95% CI: 0.96-1.04, p=0.97; Multivariate HR: 1.02, 95% CI: 0.97-1.06, p=0.47) or OS (Univariate HR: 0.99, 95% CI: 0.95-1.05, p=0.92; Multivariate HR: 1.04, 95% CI: 0.99-1.09, p=0.11), while clinical covariates (ECOG, bulky disease, prior lines, aggressive BCL) were associated with survival outcomes, as expected.

Results were consistent across 2 key subgroup analyses: 1) patients with aggressive BCL (excluding MCL, FL, MZL), 2) only patients receiving CD28-costimulatory domain CAR T cell therapy. There was no significant difference in response rates or survival outcomes in any subgroup.

Conclusion:
In this large, pooled analysis of >1,500 patients with BCL enrolled in CAR T clinical trials, the timing of CAR-T cell infusion (whether analyzed dichotomously at 12:00 PM or as a continuous variable) did not significantly impact response rate, PFS, or OS. These findings - in the absence of prospective randomized data - suggest that clinical scheduling of CAR-T infusions can be safely guided by institutional workflow and logistics rather than circadian timing.

Soon Jye Kho, PhD: Medidata Solutions - Current Employment